Related Experiment Video
Updated: Jan 28, 2026

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
Published on: June 10, 2017
Emerging epigenetic-modulating therapies in lymphoma
David Sermer1, Laura Pasqualucci2, Hans-Guido Wendel3
1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract:
Despite considerable advances in the treatment of lymphoma, the prognosis of patients with relapsed and/or refractory disease continues to be poor; thus, a continued need exists for the development of novel approaches and therapies. Epigenetic dysregulation might drive and/or promote tumorigenesis in various types of malignancies and is prevalent in both B cell and T cell lymphomas. Over the past decade, a large number of epigenetic-modifying agents have been developed and introduced into the clinical management of patients with haematological malignancies. In this Review, we provide a concise overview of the most promising epigenetic therapies for the treatment of lymphomas, including inhibitors of histone deacetylases (HDACs), DNA methyltransferases (DNMTs), enhancer of zeste homologue 2 (EZH2), bromodomain and extra-terminal domain proteins (BETs), protein arginine N-methyltransferases (PRMTs) and isocitrate dehydrogenases (IDHs), and highlight the most promising future directions of research in this area.
Insights
New epigenetic therapies offer hope for lymphoma patients with poor prognoses. This review covers promising agents targeting histone deacetylases (HDACs), DNA methyltransferases (DNMTs), and other epigenetic regulators for improved lymphoma treatment.
Area of Science:
- Oncology
- Hematology
- Epigenetics
Background:
- Relapsed/refractory lymphoma patients have poor prognoses, necessitating novel therapeutic strategies.
- Epigenetic dysregulation is a key driver in various cancers, including B cell and T cell lymphomas.
- Epigenetic-modifying agents have emerged as a significant class of drugs in hematological malignancies.
Purpose of the Study:
- To provide a concise overview of promising epigenetic therapies for lymphoma treatment.
- To highlight emerging research directions in epigenetic therapy for lymphomas.
Main Methods:
- Review of current literature on epigenetic therapies for lymphoma.
- Focus on specific epigenetic targets including HDACs, DNMTs, EZH2, BETs, PRMTs, and IDHs.
Main Results:
- Several classes of epigenetic agents show promise in preclinical and clinical settings for lymphoma.
- Inhibitors targeting HDACs, DNMTs, EZH2, BETs, PRMTs, and IDHs are under investigation.
- Ongoing research is identifying new therapeutic strategies and combinations.
Conclusions:
- Epigenetic therapies represent a vital and evolving approach to treating lymphoma.
- Targeting epigenetic mechanisms offers a promising avenue for improving outcomes in relapsed/refractory lymphoma.
- Future research should focus on optimizing these therapies and exploring novel epigenetic targets.
Related Concept Videos
Epigenetic Regulation
Epigenetic Regulation
X-chromosome...
Emerging Adulthood
Introduction Cardiac Emergencies
Gene Therapy
Applications of GIS: Disaster Management and Emergency Response

